Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | P4HTM | Q9NXG6 | 4/20 | 0.36 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | ASPH | Q12797 | 3/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | TET3 | O43151 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15739587 | 0.80 | MAPK1 (0.42) | KDM4EALDH1A1TSHRTDP1MAPT | |
| SCHEMBL10185209 | 0.79 | KDM4E (0.39) | KDM4EALDH1A1P4HTMP4HA1MIF | |
| SCHEMBL24998121 | 0.76 | P4HTM (0.34) | KDM4EALDH1A1P4HTMP4HA1MIF | |
| SCHEMBL10235699 | 0.75 | ASPH (0.41) | KDM4EALDH1A1SMN1; SMN2P4HTMP4HA1 | |
| SCHEMBL19950854 | 0.74 | KDM4E (0.49) | KDM4EALDH1A1P4HTMP4HA1MIF | |
| SCHEMBL8342650 | 0.74 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2P4HTMP4HA1 | |
| SCHEMBL31244546 | 0.73 | KDM4E (0.41) | KDM4EALDH1A1P4HTMP4HA1MIF | |
| SCHEMBL10185188 | 0.73 | ESR1 (0.44) | KDM4EALDH1A1SMN1; SMN2TSHRTDP1 | |
| SCHEMBL15718231 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL6229671 | 0.72 | KDM4E (0.44) | KDM4EALDH1A1SMN1; SMN2P4HTMP4HA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4229055-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | NOVARTIS AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| EP-4695252-A1 | IMIDAZO[1,2-A]PYRAZINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024213659-A1 | IMIDAZO[1,2-A]PYRAZINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-10-17 | — | — | WO | disclosed |
| US-12018024-B2 | Compounds and compositions for the treatment of cryptosporidiosis | NOVARTIS AG (CH) | 2024-06-25 | — | — | US | disclosed |
| EP-4229055-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | Novartis AG (CH) | 2023-08-23 | — | — | EP | disclosed |
| CN-116368137-A | Compounds and compositions for the treatment of cryptosporidiosis | 诺华股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022079616-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | NOVARTIS AG (CH) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022079616-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | NOVARTIS AG (CH) | 2022-04-21 | — | — | WO | disclosed |
| US-20220112189-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | NOVARTIS AG (CH) | 2022-04-14 | — | — | US | disclosed |
| US-9926314-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-03-27 | — | — | US | disclosed |
| US-8871754-B2 | Compounds and compositions for the treatment of parasitic diseases | IRM LLC (BM) | 2014-10-28 | — | — | US | disclosed |
| US-8871754-B2 | Compounds and compositions for the treatment of parasitic diseases | IRM LLC (BM) | 2014-10-28 | — | — | US | disclosed |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| WO-2014078802-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078813-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078813-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110206661-A1 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2010078408-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206661-A1 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE | ABL1, LCK, SRC | KDM4E 563/4885ALDH1A1 2473/4885SMN1; SMN2 4191/4885 |
| US-20220112189-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | SLC10A2, SI, SLC10A1 | KDM4E 3230/4885ALDH1A1 2041/4885SMN1; SMN2 1568/4885 |
| US-12018024-B2 | Compounds and compositions for the treatment of cryptosporidiosis | SLC10A2, SI, SLC10A1 | KDM4E 3230/4885ALDH1A1 2041/4885SMN1; SMN2 1568/4885 |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDM4E 2722/4885ALDH1A1 1934/4885SMN1; SMN2 4529/4885 |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | KDM4E 2347/4885ALDH1A1 1143/4885SMN1; SMN2 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.